BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36607147)

  • 1. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
    DerSarkissian M; Cranmer H; Dabora J; Bocharova I; Cherepanov D; Cheng M; Bhak RH; Duh MS
    Hematology; 2023 Dec; 28(1):2156731. PubMed ID: 36607147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
    Ailawadhi S; Cheng M; Cherepanov D; DerSarkissian M; Stull DM; Hilts A; Chun J; Duh MS; Sanchez L
    Curr Probl Cancer; 2024 Jun; 50():101078. PubMed ID: 38547609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
    Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
    Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
    Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
    BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
    Mohyuddin GR; Hampton J; Aziz M; Khuder S; Malik S; McClune B; Abdallah AO
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):489-496. PubMed ID: 33962898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
    Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
    Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
    Minarik J; Radocha J; Jungova A; Straub J; Jelinek T; Pika T; Pour L; Pavlicek P; Harvanova L; Pospisilova L; Krhovska P; Novakova D; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Maisnar V; Hajek R
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
    Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
    Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).
    Liu J; Yang H; Liang X; Wang Y; Hou J; Liu Y; Wang J; Zhou F
    Oncotarget; 2017 Sep; 8(37):62435-62444. PubMed ID: 28977957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
    Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
    Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
    Chen H; Chen H; Zhou Y; Xu W; Yu J; Xu Y; Zhou F
    Hematology; 2023 Dec; 28(1):2225342. PubMed ID: 37343159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
    Abe Y; Sasaki M; Takezako N; Ito S; Suzuki K; Handa H; Chou T; Yoshida T; Mori I; Shinozaki T; Suzuki K
    Ann Hematol; 2023 Sep; 102(9):2493-2504. PubMed ID: 37341778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.
    Schmitz S; Maguire Á; Morris J; Ruggeri K; Haller E; Kuhn I; Leahy J; Homer N; Khan A; Bowden J; Buchanan V; O'Dwyer M; Cook G; Walsh C
    BMC Med Res Methodol; 2018 Jun; 18(1):66. PubMed ID: 29954322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
    Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
    Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
    Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
    J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
    Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
    Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
    Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.